Nanogroup

Nanogroup Net Margin

The Net Profit Margin of Nanogroup (NNG.WA) as of Oct 22, 2026 is -246,079.19 %. In the previous year, Net Profit Margin was -390,778.60 % — a change of -37.03% (higher).

Net Margin

-246,079.19 %

YoY

-37.03%

Last updated:

Net Profit Margin of Nanogroup is 2024 -246,079.19 % . Net Profit Margin of Nanogroup was 2023 -390,778.60 % . It decreases by -37.03% higher compared to the previous year.

For Nanogroup, the net margin of -246,079.2% is down versus -754.8% a few years ago.

The Nanogroup Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
-4,935.10 PLN
Jan 1, 2018
-2,125.87 PLN
Jan 1, 2019
-437.04 PLN
Jan 1, 2020
-754.79 PLN
Jan 1, 2021
-2,031.60 PLN
Jan 1, 2022
-600.93 PLN
Jan 1, 2023
-390,778.60 PLN
Jan 1, 2024
-246,079.19 PLN
The Nanogroup Net Margin history
YEARNet MarginYoY
-246,079.19 %-37.03%
-390,778.60 %+64,928.96%
-600.93 %-70.42%
-2,031.60 %+169.16%
-754.79 %+72.71%
-437.04 %-79.44%
-2,125.87 %-56.92%
-4,935.10 %-48.99%
-9,674.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanogroup Stock analysis

What does Nanogroup do? NanoGroup SA generates revenue through its advanced biotechnological projects focused on cancer prevention, early diagnosis, and targeted therapies. The company's portfolio includes NanoVelos, which develops drug delivery systems for oncologic medicines, and NanoSanguis, which creates artificial blood for accident victims and an organ preservation system called Organ farm. NanoThea specializes in early cancer detection technology. These products are sold to medical institutions, research facilities, and healthcare providers seeking innovative solutions in oncology and organ preservation. The firm's revenue streams come from licensing agreements and direct sales of its biotechnological solutions. NanoVelos targets pharmaceutical companies needing optimized drug delivery, while NanoSanguis serves emergency medical services and trauma centers requiring artificial blood and organ preservation. NanoThea's early cancer detection systems are purchased by diagnostic centers and hospitals aiming to improve patient outcomes through early intervention. NanoGroup SA's business model relies on the commercialization of its R&D projects, with each brand addressing specific medical needs. The company's focus on cancer-related technologies and organ preservation positions it as a key supplier in the biotech sector, serving healthcare providers and research organizations that require cutting-edge medical solutions. Nanogroup is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanogroup stock

Net Profit Margin of Nanogroup is -246,079.19 % in 2024.

Net Profit Margin of Nanogroup changed from -390,778.60 % to -246,079.19 %, representing a -37.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Nanogroup since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Nanogroup with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Nanogroup

All Key Metrics — Nanogroup